Skip to content
TrialScanner

NCT03066258

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Phase 1/Phase 2CompletedRGNXLead

Registry record

Lead sponsor
REGENXBIO Inc.
Conditions
Neovascular Age-related Macular Degeneration; Wet Age-related Macular Degeneration
Primary completion
Nov 24, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03066258 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03066258: Safety and Tolerability of... | TrialScanner